Glythera, Iontas Launch Cancer ADC Collaboration

Glythera will use novel, fully human antibodies supplied by Iontas to develop next-generation antibody–drug conjugates (ADCs) against unspecified “difficult-to-treat” cancers, the companies said today, under a collaboration whose value was not disclosed.The companies did say, however, that Iontas will receive undisclosed development and clinical milestone payments on each ADC developed, while Glythera will oversee the development, manufacturing, and commercialization of any ADC